Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

Prostate cancer is the most common malignant tumor in men, accounting for 29% of male neoplasm diagnoses in the United States alone. Radical prostatectomy remains the preferred treatment for localized ...

In patients with a high suspicion of prostate cancer as determined by molecular imaging, avoiding biopsy prior to radical prostatectomy appeared to be feasible, and "might represent a valid option in ...

With Men’s Health Week approaching, it is a good time to encourage open discussions about various health conditions, particularly prostate health. Driven by embarrassment, misconceptions, and a lack ...

Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of advanced prostate cancer: Data from a 52-week clinical trial. Real-world use and outcomes of ...

There is ongoing clinical need to improve estimates of disease outcome in prostate cancer. Machine learning (ML) approaches to pathologic diagnosis and prognosis are a promising and increasingly used ...

RP appears more protective than RT among men with actively treated incidental prostate cancer. Patients with higher-grade incidentally discovered prostate cancer (IPCa) may have better outcomes if ...

Radical prostatectomy does not ensure a cure, with one in three men experiencing cancer recurrence and elevated PSA levels within 10 years post-surgery. Significant side effects of prostate removal ...

Up to 72% of patients with prostate cancer who undergo radical prostatectomy experience urinary incontinence in the first 3 months after surgery. Up to 72% of patients experience urinary incontinence ...